NEW ORLEANS — At the American Society of Cataract and Refractive Surgery meeting, Brian Francis, MD, discusses the use of ECP-plus in glaucoma patients who have failed multiple other interventions for substantial IOP reduction and ECP-L in glaucoma patients with severe plateau iris syndrome.
NEW ORLEANS — Raymond Stein, MD, FRCSC, shared pearls for performing topography-guided photorefractive keratectomy in combination with corneal cross-linking for the management of keratoconus here at Cornea Day preceding the American Society of Cataract and Refractive Surgery meeting. “This technique can arrest the disease and improve best corrected spectacle visual acuity,” Stein said.
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Penny A. Asbell, MD, FACS, MBA, relates the message that not all antibiotics work for all organisms, as demonstrated in the ARMOR study. Of 172 samples collected from aqueous or vitreous, coagulase-negative staphylococci were found in 100 samples, making it a common cause of infection, she said.
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Penny A. Asbell, MD, FACS, MBA, advises ophthalmologists to “pick wisely” when choosing antibiotics for their patients. More than 30% of Staphylococcus aureus is antibiotic resistant, she said, and keeping abreast of nationwide surveillance data, such as that reported in the ARMOR study, can help ophthalmologists initially decide which antibiotic is appropriate.
NEW ORLEANS — Glaucoma patients implanted with a bimatoprost ocular insert showed a clinically relevant reduction in IOP over 6 months, according to a study presented here. “[In patients with ocular hypertension], we found that lowering IOP by 20% will decrease the relevant risk of developing glaucoma by 60% among the subjects in our study, and if we achieve this sort of efficacy level, we can prevent many patients from diurnal loss and developing vision loss,” John D. Brandt, MD, said at the Ophthalmology Innovation Summit preceding the American Society of Cataract and Refractive Surgery meeting.
Years before inflammatory bowel disease (IBD) is diagnosed and symptoms exist, biomarkers are already circulating that can help predict risk not only of disease development but also of complications, according to research published online last week, which will also appear in the June 15th print issue of Alimentary Pharmacology & Therapeutics.